CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
CVRx is focused on the development and commercialization of the Barostim System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit .MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.
明尼阿波利斯，2024年11月20日（環球新聞社） - CVRx，Inc.（納斯達克：CVRX）（"CVRx"），一家商業化階段的醫療器械公司，今日宣佈管理團隊將於2024年12月4日星期三參加派傑投資第36屆醫療健康大會。公司計劃於當天下午3:30通過網絡直播進行演示。
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com.
會議演示的現場音頻網絡直播將在公司網站的投資者關係頁面ir.cvrx.com上線。
About CVRx, Inc.
CVRx, Inc. 簡介。CVRx 是一家商業化醫療器械公司，專注於爲心血管疾病患者開發、製造和銷售創新的神經調節解決方案。Barostim 是首個 FDA 批准使用神經調節技術改善心力衰竭症狀的醫療技術。Barostim 爲可植入設備，向頸動脈壁的壓力感受器提供電脈衝。該療法旨在恢復自主神經系統的平衡，從而減輕心衰症狀。Barostim 獲得 FDA 創新設備認證，已獲得 FDA 批准在美國人群中使用以治療心衰病患者，也已獲得歐洲經濟區治療心衰病和難治性高血壓的 CE 認證。要了解有關 Barostim 的更多信息，請訪問網站。
CVRx is focused on the development and commercialization of the Barostim System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit .
CVRx致力於開發和商業化Barostim系統，這是FDA首次批准使用神經調節改善心力衰竭症狀的醫療技術。Barostim是一種植入式器械，它向頸動脈壁中的壓力感受器傳遞電脈衝。壓力感受器激活人體的壓力感受器反射，進而觸發自主神經對心臟的反應。該療法旨在恢復自主神經系統的平衡，從而減輕心力衰竭的症狀。Barostim獲得FDA突破性設備認定，並獲得美國心力衰竭患者使用的FDA批准。它還獲得了歐洲經濟區心力衰竭和難治性高血壓的CE標誌。欲了解Barostim的更多信息，請訪問網站。
Investor Contact:
投資者聯繫人：
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Mark Klausner或Mike Vallie
ICR 醫療保健
443-213-0501
ir@cvrx.com
Media Contact:
媒體聯繫：
Laura O'Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
Laura O'Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
